(1) These Regulations may be cited as the Unlicensed Medicinal Products for Human Use (Transmissible Spongiform Encephalopathies) (Safety) Regulations 2003 and shall come into force on 30th July 2003.
(2) In these Regulations—
“the 1968 Act” means the Medicines Act 1968 ;
“the 1987 Act” means the Consumer Protection Act 1987;
...
“ the 2012 Regulations ” means the Human Medicines Regulations 2012;
“ the appropriate committee ” means whichever the appropriate Minister considers to be the appropriate body of the following—
the Commission; or
an expert committee appointed by the appropriate Minister, or by the appropriate Ministers for Great Britain and for Northern Ireland acting jointly;
“the appropriate Minister” means—
in Great Britain, the Secretary of State;
in Northern Ireland, the Minister of Health, Social Services and Public Safety;
“ the Commission ” means the Commission on Human Medicines continued in existence by regulation 9 of the 2012 Regulations;
...
“ excluded medicine ” means a medicinal product to which the restrictions in regulation 46 (requirement for authorisation) of the 2012 Regulations do not apply by virtue of regulation 3(6) (scope of these Regulations: special provisions) or 4(1) (special provisions for pharmacies etc) of those Regulations;
...
“import” means, in relation to an unlicensed product, import into the United Kingdom in the course of a business other than for the purposes of a clinical trial;
“market” means, in relation to an unlicensed product, a supply of the product, other than for the purposes of a clinical trial, which is also—
the occasion on which the product is placed on the market in the United Kingdom;
any occasion on which the product is distributed by way of wholesale dealing within the United Kingdom; or
the exportation of the product out of the United Kingdom,
and for these purposes, “placed on the market” and “distributed by way of wholesale dealing” are to be construed in accordance with the 2012 Regulations;
“ medicinal product ” has the meaning given by regulation 2 of the 2012 Regulations;
“supply”, in relation to an unlicensed product, means—
the supply of, or the offer or agreement to supply, the product; or
the exposure or possession for supply of the product;
“ unlicensed product ” means—
in the case of a product to be imported or marketed in Great Britain, a medicinal product for human use, other than an excluded medicine, in respect of which no UKMA(GB), UKMA(UK), THR(UK) or THR(GB) has been granted;
in the case of a product to be imported or marketed in Northern Ireland, a medicinal product for human use, other than an excluded medicine, in respect of which no UKMA(NI), UKMA(UK), THR(UK) or THR(NI), EU marketing authorisation or Article 126a authorisation has been granted,
and “Article 126a authorisation”, “EU marketing authorisation”, “THR(GB)”, “THR(NI)”, “THR(UK)”, “UKMA(GB)”, “UKMA(NI)” and “UKMA(UK)” have the meanings given in regulation 8 of the 2012 Regulations;
“the TSE Guideline” means the “Note for guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products” as published and updated by the European Commission in Volume 3 of its publication, “The Rules Governing Medicinal Products in the European Union”, referred to in the Introduction to the Annex to Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as substituted by Commission Directive 2003/63/EC amending Directive 2001/83/EC on the Community code relating to medicinal products for human use .
(3) In these Regulations, a reference—
(a) to a numbered regulation, is to the regulation of these Regulations bearing that number;
(b) in a regulation, to a numbered paragraph is to the paragraph of that regulation bearing that number.